TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04997889

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercial artificial salivary
Description: The commercial artificial salivary will be used 2 g/time (3 times/day) into the mouth for 6 days. Then, the commercial artificial salivary will be stopped for 7-10 days. After that, the commercial artificial salivary will be used 2 g/time (3 times/day) into the mouth for 3 days.
Study: NCT06476327

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: experimental 2 group
Description: Participants will undergo a total of 20 training sessions, five times a week for four weeks, with each session lasting 30 minutes. Participants will have a 4-minute break during the 30-minute gait training session.~Participants will be given a period to adapt to wearing the robot, and after that, the intervention will be conducted based on each participant's individual abilities and adaptation.
Study: NCT06430047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EsoDuo® Tablet
Description: QD, PO
Study: NCT05339438

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: functional MRI
Description: Functional MRI scanning (around 1h30 min): SMS + multi-band (with FPVS paradigms for both)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: functional MRI
Description: Functional MRI scanning (around 1h30 min): SMS + multi-band (with FPVS paradigms for both)
Study: NCT04645017

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intergenerational Music Program
Description: Music activities will be lead by adolescent musicians for older adult participants.
Study: NCT04718181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risdiplam
Description: Risdiplam will be administered orally at a single dose of 5 mg in different formulations. Dispersible tablet formulations (F21/F22) will be administered as swallowed tablet or as tablet dispersed in water. The powder for constitution to an oral solution will be administered as an oral solution constituted with purified water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risdiplam
Description: Risdiplam will be administered orally at a single dose of 5 mg in different formulations. Dispersible tablet formulations (F21/F22) will be administered as swallowed tablet or as tablet dispersed in water. The powder for constitution to an oral solution will be administered as an oral solution constituted with purified water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risdiplam
Description: Risdiplam will be administered orally at a single dose of 5 mg in different formulations. Dispersible tablet formulations (F21/F22) will be administered as swallowed tablet or as tablet dispersed in water. The powder for constitution to an oral solution will be administered as an oral solution constituted with purified water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: Omeprazole will be administered orally as a capsule at a dose of 40 mg per day
Study: NCT05813327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI PEG20
Description: ADI-PEG 20 will be given on an outpatient basis at a dose of 36 mg/m\^2 via intramuscular injection into either the deltoid or gluteal muscle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI PEG20
Description: ADI-PEG 20 will be given on an outpatient basis at a dose of 36 mg/m\^2 via intramuscular injection into either the deltoid or gluteal muscle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide will be administered intravenously per package insert and institutional practice on Days 1 through 5 of all 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide will be administered intravenously per package insert and institutional practice on Days 1 through 5 of all 3 cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy will begin on C2D1 and will continue as per institutional practice.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy will begin on C2D1 and will continue as per institutional practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna will be administered for supportive care either intravenously or by mouth per package insert and institutional practice on Days 1 through 5 of all 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna will be administered for supportive care either intravenously or by mouth per package insert and institutional practice on Days 1 through 5 of all 3 cycles.
Study: NCT06012487

Intervention type: DRUG
Group type: OTHER
Intervention: Low BPV Regimen
Description: Each the patients' physician will invite patients to complete a 48-hour ABPM, then undergo cross-titration from their current antihypertensive regimen to a low BPV regimen, consisting of Amlodipine and Indapamide. Study staff will suggest to the treating physician to initially start patients on Amlodipine 5mg daily, with uptitration to 10mg daily to a goal systolic blood pressure (SBP)\<130 mmHg. Indapamide will be suggested to be added at 1.25mg daily and increased to 2.5mg daily, as needed to meet target SBP. Other antihypertensive medications will be suggested to be discontinued as the SBP target is reached. Patients not meeting target SBP on maximally tolerated Amlodipine and Indapamide will be suggested to have a long acting angiotensin-converting enzyme (ACE)/ angiotensin receptor blocker (ARB) added to their therapy. Patients will complete another 48-hour ABPM after 1 week at target SBP on the low-BPV regimen.
Study: NCT05276596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: The control group will be taken care of according to the protocols in force. The first anesthetic post-induction hypotension will be managed by intravenous injection of ephedrine (dilution: 3 mg / ml) at a dose of 6 mg (i.e. 2 ml). Any subsequent hypotension will be treated with ephedrine until injection of a total dose of 30 mg. Thereafter, if a new arterial hypotension occurs, we will pass to the administration of noradrenaline in intravenous injection using an electric syringe pump, at the dilution of 0.016 mg / ml, posology adapted to the objectives. blood pressure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Immediately use of norepinephrine by intravenous injection using an electric syringe pump, at a dilution of 0.016 mg / ml, at the time of anesthetic induction and without waiting the 1st possible arterial hypotension. Noradrenaline will be started at a dose of 0.48 mg / h and then adapted according to the blood pressure objectives.
Study: NCT06043726

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory testing: D-dimeer and astrup
Description: Standard care: Laboratory result (D-dimer and astrup). CT scan for pulmonary embolism if indicated
Study: NCT04879628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441344 IV
Description: Pharmaceutical form: Solution Route of administration: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo IV
Description: Pharmaceutical form: Solution Route of administration: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441344 SC
Description: Pharmaceutical form: Solution Route of administration: SC injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo SC
Description: Pharmaceutical form: Solution Route of administration: SC injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MRI contrast-enhancing preparations
Description: gadolinium compound, including but not limited to Magnevist, Multihance, Prohance, or Elucirem

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRI contrast-enhancing preparations
Description: gadolinium compound, including but not limited to Magnevist, Multihance, Prohance, or Elucirem

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MRI contrast-enhancing preparations
Description: gadolinium compound, including but not limited to Magnevist, Multihance, Prohance, or Elucirem

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRI contrast-enhancing preparations
Description: gadolinium compound, including but not limited to Magnevist, Multihance, Prohance, or Elucirem
Study: NCT03395392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRX-101
Description: NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lurasidone HCl
Description: Lurasidone HCl will be given twice a day by mouth
Study: NCT05446896

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AR guidance with Hololens 2
Description: The AR instructions were developed as a step-by-step guide with the same text and images as in the printed manual, utilizing the dynamic 365 Guide (Software, Microsoft Corporation, Redmond, WA, USA). The AR instructions were delivered using the Microsoft HoloLens 2.
Study: NCT06628895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXERCISE TRAINING WITH OR WITHOUT MEDICATION
Description: Exercise training that consists of flexibility, aerobic, balance and strengthening regime. The exercise given three times a week, for 12 weeks.
Study: NCT04602936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solriamfetol
Description: Solriamfetol is a novel DNRI (novel dopamine and norepinephrine reuptake inhibitor) that has recently received regulatory approval for the treatment of excessive daytime sleepiness in individuals with narcolepsy or obstructive sleep apnea.
Study: NCT06416852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Alfatide Injection
Description: A single dose of (0.1\~0.15）±0.015 mCi/kg IV injection of 18F-Alfatide. The patients will be intravenously injected with 18F-Alfatide Injection and undergo PET/CT scan at 60 min±10 min after the injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG Injection
Description: A single dose of 5～10mCi IV injection of 18F-FDG. The patients will be intravenously injected with 18F-FDG Injection and undergo PET/CT scan at 40 min±10 min after the injection.
Study: NCT05123196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554
Description: Oral Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Capsule
Study: NCT05024123

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Before each study day, the participants were subjected to a reduced nitrate content diet (avoid foods such as dark chocolate, beets, garlic, nuts and seeds, bacon, ham, and hot dogs,, day-1) for 24h. All subjects took a 50 mg placebo (maltodextrin) capsule at 9 p.m. and began fasting for 12 hours, except for a small amount of water in the night before the experiment. On each study day, all subjects collected their first blood sample at 9 a.m. from the median cubital vein using the indwelling catheter method. After the first blood collection, all subjects took 50 mg placebo and 5 g of L-arginine with 250 mL water.~Additional blood samples were collected at 0, 15, 30, 45, 60, 90, 120, 150, and 180 min for analysis of the plasma concentration of amino acids, total nitrite, nitrate, and asymmetric dimethylarginine (ADMA) content.~All subjects collected their urine during 0 \~ 180 min to measure 1) nitrate and 2) cGMP content.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AstraGin
Description: Before each study day, the participants were subjected to a reduced nitrate content diet (avoid foods such as dark chocolate, beets, garlic, nuts and seeds, bacon, ham, and hot dogs,, day-1) for 24h. All subjects took a 50 mg placebo (maltodextrin) capsule at 9 p.m. and began fasting for 12 hours, except for a small amount of water in the night before the experiment. On each study day, all subjects collected their first blood sample at 9 a.m. from the median cubital vein using the indwelling catheter method. After the first blood collection, all subjects took 50 mg placebo and 5 g of L-arginine with 250 mL water.~Additional blood samples were collected at 0, 15, 30, 45, 60, 90, 120, 150, and 180 min for analysis of the plasma concentration of amino acids, total nitrite, nitrate, and asymmetric dimethylarginine (ADMA) content.~All subjects collected their urine during 0 \~ 180 min to measure 1) nitrate and 2) cGMP content.
Study: NCT05862324

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAC01-CLDN18.2
Description: TAC01-CLDN18.2 preceded by lymphodepletion with fludarabine or clofarabine, cyclophosphamide, and nab-paclitaxel.
Study: NCT05238467

Intervention type: OTHER
Intervention: COVID antibody titers in the blood
Description: COVID antibody titers will be quantitatively assessed at baseline, 8 weeks and approximately 6, 9, and 12 months from date of study enrollment. Titers will be compared to levels in 25 age matched adult participants with no prior history of cancer or prior history of non-metastatic solid cancer invasive cancer treated with a curative intent,.and in 25 age matched cancer participants who are on non-immunosuppressive treatments as defined below.

Intervention type: OTHER
Intervention: COVID antibody titers in the blood
Description: COVID antibody titers will be quantitatively assessed at baseline, 8 weeks and approximately 6, 9, and 12 months from date of study enrollment. Titers will be compared to levels in 25 age matched adult participants with no prior history of cancer or prior history of non-metastatic solid cancer invasive cancer treated with a curative intent,.and in 25 age matched cancer participants who are on non-immunosuppressive treatments as defined below.

Intervention type: OTHER
Intervention: COVID antibody titers in the blood
Description: COVID antibody titers will be quantitatively assessed at baseline, 8 weeks and approximately 6, 9, and 12 months from date of study enrollment. Titers will be compared to levels in 25 age matched adult participants with no prior history of cancer or prior history of non-metastatic solid cancer invasive cancer treated with a curative intent,.and in 25 age matched cancer participants who are on non-immunosuppressive treatments as defined below.
Study: NCT04304755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid 5 MG in 5 ML Injection
Description: Zoledronic acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: NaCl 0.9%
Study: NCT06403228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Structured Nursing Interventions
Description: In the study, 8 days of mindfulness-based structured nursing interventions were applied to high-risk pregnant women. The program lasts 60 minutes each day. The program includes short body scanning meditation, breath awareness meditation, sitting meditation, compassion meditation.
Study: NCT05763095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Intervention for Emotional Distress
Description: Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
Study: NCT06372301

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography
Description: Patients will be investigated with dobutamine stress echocardiography (increasing doses of dobutamine infusion and simulatneous echocardiogarphic evaluation) to assess aortic valve area and projected aortic valve area.
Study: NCT05992181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NEORTHO
Description: early orofacial stimulation
Study: NCT05282264

Intervention type: OTHER
Intervention: device
Description: closed-loop insulin
Study: NCT04696055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 400 mg to be administered as an intravenous (IV) infusion every 6 weeks (Q6W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Regorafenib to be given orally (p.o.) at a starting dose of 90 mg QD for 3 weeks of every 4 weeks (i.e., 3 weeks on, 1 week off). If the starting dose of 90 mg daily is well tolerated the dose should be escalated to 120 mg starting after the first 4-week cycle of regorafenib.
Study: NCT06552312

Intervention type: OTHER
Intervention: Delphi Questionnaire
Description: Experts will be asked to rate the importance of each item for ECPR for OHCA using the Grading of Recommendations Assessment, Development and evaluation scale from 1 (strongly disagree) to 9 (strongly agree). The median score (IQR) will be calculated after eliminating one lowest and one highest value after each survey round. Statements will be classified as strong agreement (median score 7-9), neither agree or disagree (median score 4-6), or strongly disagree (median score 1-3). Panel members were also provided an Unable to Score response to use if they did not feel comfortable rating any specific domain. Recipients will be asked to recommend any wording/phrasing changes and to suggest any additional items for inclusion.
Study: NCT05081648

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT MuST
Description: Multiple Single Cannulation Technique (MuST): Experimental technique
Study: NCT05004064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Patients will receive acalabrutinib 100mg twice daily for up to six 28 day cycles. Patients can receive 100mg once daily for cycle 1, day 1 to day 7, according to the investigator's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patient will receive rituximab 375 mg/m2 IV on day 1 (+/- 3 days) of each cycle, for a maximum of 6 cycles
Study: NCT05301686

Intervention type: PROCEDURE
Intervention: Patients with Cyclop lesion
Description: Arthroscopy with resection of Cyclop formation

Intervention type: PROCEDURE
Intervention: Patients with Cyclop lesion
Description: Arthroscopy with resection of Cyclop formation
Study: NCT05516888

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency of gasserian ganglion
Description: radiofrequency ablation of the gasserian ganglion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency of the peripheral trigeminal branches
Description: radiofrequency of the peripheral trigeminal branches ( maxillary, mandibular, supraorbital)
Study: NCT05069519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Smartwatch
Description: Participants will continue with standard care, but will receive a Fitbit and be encouraged to participate in at least 150 min. moderate-to-vigorous physical activity (5 sessions aerobic exercise, 30 min. per session; and 2 sessions of strength training) per week if their body condition allows throughout the intervention period. The previously established daily and weekly exercise prescription will be offered to participants based on their previous week Fitbit data.~PA improvements will be tailored over time based on each participant's previous week PA and they will be encouraged to increase PA by 5-10 min/week if possible depending on specific situations. Participants will save each workout and synchronize the Fitbit PA data to its app where they only share daily data and receive weekly personalized exercise prescriptions established in pilot studies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Smartwatch
Description: Participants will continue with standard care, but will receive a Fitbit and be encouraged to participate in at least 150 min. moderate-to-vigorous physical activity (5 sessions aerobic exercise, 30 min. per session; and 2 sessions of strength training) per week if their body condition allows throughout the intervention period. The previously established daily and weekly exercise prescription will be offered to participants based on their previous week Fitbit data.~PA improvements will be tailored over time based on each participant's previous week PA and they will be encouraged to increase PA by 5-10 min/week if possible depending on specific situations. Participants will save each workout and synchronize the Fitbit PA data to its app where they only share daily data and receive weekly personalized exercise prescriptions established in pilot studies.
Study: NCT05081648

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rope-ladder cannulation technique
Description: Standard cannulation technique( Rope-ladder)
Study: NCT04834882

Intervention type: OTHER
Intervention: Data collection (
Description: online survey
Study: NCT06206668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action observation videos
Description: The participant will see videos of balance exercises performed by the assigned reference, depending on their group, without performing any physical movement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Action observation videos
Description: The participant will see videos of balance exercises performed by the assigned reference, depending on their group, without performing any physical movement.
Study: NCT06324994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linperlisib in combination with Obinutuzumab and Venetoclax
Description: Combined induction period: Linprixate: 80 mg, oral (pre - and post meal), once a day; Otuzumab: 1000 mg/dose, intravenous infusion, administered on the first day (1st cycle is 1, 8, 15 days); (Up to 6 cycles, administration cycle can be adjusted according to clinical treatment conditions); Vineclavone: increase from 40mg, 100mg, and 200mg to 400mg within 4 weeks, followed by a treatment cycle of 400mg orally once a day; (Starting from the third cycle), one cycle every 28 days, for a total of 6 cycles。 Maintenance treatment period: Linprixate: 80 mg, oral (both before and after meals), once a day; Vinecala: 400 mg, oral, once daily; Cycle every 28 days.